4//SEC Filing
Brophy Gerard 4
Accession 0001722482-23-000023
CIK 0001722482other
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 8:25 PM ET
Size
8.7 KB
Accession
0001722482-23-000023
Insider Transaction Report
Form 4
Avantor, Inc.AVTR
Brophy Gerard
EVP, Biopharma Production
Transactions
- Sale
Common Stock
2023-02-02$25.06/sh−11,339$284,155→ 102,385 total - Tax Payment
Common Stock
2023-01-31$23.90/sh−15,221$363,782→ 113,724 total - Award
Common Stock
2023-01-31+38,737→ 128,945 total
Footnotes (4)
- [F1]Reflects performance-based restricted stock units previously granted to the Reporting Person, the performance of which was certified on January 31, 2023. Each performance-based restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer.
- [F2]Reflects shares of Common Stock withheld to cover the Reporting Person's tax liability in connection with the vesting and settlement of the performance-based restricted stock units described herein.
- [F3]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $25.00 to $25.15, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above.
Documents
Issuer
Avantor, Inc.
CIK 0001722482
Entity typeother
Related Parties
1- filerCIK 0001776107
Filing Metadata
- Form type
- 4
- Filed
- Feb 1, 7:00 PM ET
- Accepted
- Feb 2, 8:25 PM ET
- Size
- 8.7 KB